Cell Therapeutics (CTIC) Q2 2012 Earnings Call August 01, 2012 8:30 am ET Executives James A. Bianco - Principal Founder, Chief Executive Officer, President and Executive Director
TheStreet's biotech columnist offers his own report card on biotech stocks.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
Stocks with insider trader activity include LPNT, PATK and CTIC
Stocks with insider trader activity include SPTN, FL and CTIC